{"entity":{"id":"nct03562637","kind":"trial","name":"Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC","aka":[],"tldr":"A phase 3 trial of Adagloxad simolenin run by OBI Pharma, Inc, active.","summary":"Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC is a phase 3 interventional study registered as NCT03562637 by OBI Pharma, Inc, with 575 participants enrolled, started 2018-12-05. Conditions listed: Triple Negative Breast Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03562637","url":"https://clinicaltrials.gov/study/NCT03562637"}],"tags":["ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["adagloxad-simolenin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03562637","phase":"3","setting":"The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With High Risk, Early Stage Globo H-Positive Triple Negative Breast Cancer","sponsor":"OBI Pharma, Inc","enrolled":575,"outcomes":[]},"route":"/trials/nct03562637/","neighbours":{"drug":[{"id":"adagloxad-simolenin","kind":"drug","name":"Adagloxad simolenin","route":"/drugs/adagloxad-simolenin/"}]}}